288569-60-8 Usage
Description
1-cyanocyclopropyl 4-methylbenzenesulfonate, an organic compound with the chemical formula C11H9NO2S, is a white crystalline solid that serves as a versatile chemical reagent in organic synthesis. Known for its reactivity with nucleophiles and its ability to undergo substitution reactions, this compound is a valuable building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. However, due to its toxic and irritant properties, it requires careful handling and use.
Uses
Used in Pharmaceutical Industry:
1-cyanocyclopropyl 4-methylbenzenesulfonate is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to facilitate the formation of new chemical entities through substitution reactions.
Used in Agrochemical Industry:
In the agrochemical sector, 1-cyanocyclopropyl 4-methylbenzenesulfonate is utilized as a precursor in the development of new agrochemicals, contributing to the creation of innovative products for crop protection and enhancement.
Used in Organic Synthesis:
As a building block in organic synthesis, 1-cyanocyclopropyl 4-methylbenzenesulfonate is employed for the preparation of a wide range of organic compounds, expanding the scope of chemical research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 288569-60-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,8,5,6 and 9 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 288569-60:
(8*2)+(7*8)+(6*8)+(5*5)+(4*6)+(3*9)+(2*6)+(1*0)=208
208 % 10 = 8
So 288569-60-8 is a valid CAS Registry Number.
288569-60-8Relevant articles and documents
XANTHINE CB1 INHIBITORS
-
Page/Page column 148-149, (2021/04/02)
Disclosed are compounds having structural formula (I), and related pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating diseases such as diabetic kidney disease, diabetic nephropathy, obesity-related kidney disease, focal segmental glomerular sclerosis, IgA nephropathy, nephrotic syndrome, kidney fibrosis, Prader Willi syndrome, metabolic syndrome, gastrointestinal diseases, non-alcoholic liver disease, alcoholic liver disease, or non-alcoholic fatty liver disease, using the compounds of Formula (I).
Novel Compounds
-
Paragraph 0699-0701, (2017/07/06)
The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an RORγ and/or RORγt mediated disease state.
MACROCYCLIC FACTOR VIIA INHIBITORS
-
Paragraph 00287; 00288, (2014/01/08)
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.